Please ensure Javascript is enabled for purposes of website accessibility

Why PTC Therapeutics, Tellurian, and B&G Foods Slumped Today

By Dan Caplinger - Mar 16, 2017 at 4:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These stocks led the market lower. Find out why.

Thursday was a modestly negative day for the stock market, as major market benchmarks posted very small losses to reverse some of their big gains from Wednesday. In the wake of higher interest rates from the Federal Reserve, investors are beginning to turn their attention to the coming first-quarter earnings season that starts early next month. Moreover, investors seemed content to wait and see whether political wrangling in Washington will result in meaningful policy changes or a continuation of the gridlock that has plagued the capital city for years.

Losses for the broad market were minimal, but some stocks posted much larger declines. PTC Therapeutics (PTCT 4.47%), Tellurian (TELL 0.34%), and B&G Foods (BGS 1.60%) were among the worst performers on the day. Below, we'll look more closely at these stocks to tell you why they did so poorly.

PTC makes a deal, but investors are skeptical

Shares of PTC Therapeutics dropped 19% after the company announced its fourth-quarter financial results and said that it would spend $140 million to purchase rights to a controversial drug. PTC's revenue doubled from year-ago levels on the strength of its Translarna treatment for Duchenne muscular dystrophy (DMD), and net losses fell by roughly half compared to the fourth quarter of 2015. However, what most investors focused on was PTC's announcement that it would buy rights to rival DMD drug Emflaza, paying Marathon Pharmaceuticals $75 million in cash plus $65 million in PTC stock. PTC CEO Stuart Peltz said that "it is deeply meaningful for us to bring this critical therapy to U.S. patients," but some shareholders noted that Marathon has been the subject of political criticism because of the drug's high price tag. Given an uncertain future for drug companies based on current sentiment in Washington, today's share price drop reflects the belief that PTC might have overpaid for the controversial drug.

Researcher in a lab.

Image source: PTC Therapeutics.

Tellurian looks to offer shares

Tellurian stock dropped 16% in the wake of a filing with the U.S. Securities and Exchange Commission stating its intent to make secondary offerings of its stock. The filing will allow Tellurian to sell up to $200 million in stock, which would represent almost 10% of its current $2.15 billion market capitalization. Tellurian has attracted substantial interest from the investment community, with French oil giant Total having bought a 23% stake in the company at $5.85 per share for roughly $207 million just last December. The stock climbed above $20 late last month, but it has since given up substantial ground as investors weigh the prospects for its Driftwood liquefied natural gas project. Investors can expect further volatility from Tellurian, especially with the ability to sell shares in the future.

B&G leaves investors hungry with CFO departure

Finally, shares of B&G Foods dropped 6%. The food company behind the Cream of Wheat, Grandma's Molasses, and Ortega brands said that CFO Tom Crimmins has resigned to pursue other opportunities. In response, B&G said that corporate controller Amy Chiovari would become interim chief financial officer following Crimmins' departure later this month. CEO Robert Cantwell reassured investors that the transition would be smooth and that the decision was amicable, expressing his confidence in Chiovari's abilities. Nevertheless, the stock had already started losing ground before the announcement, and uncertainty regarding the company's future sent the stock to levels it hasn't seen in nearly a year.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

B&G Foods, Inc. Stock Quote
B&G Foods, Inc.
BGS
$24.16 (1.60%) $0.38
PTC Therapeutics, Inc. Stock Quote
PTC Therapeutics, Inc.
PTCT
$41.85 (4.47%) $1.79
Tellurian Inc. Stock Quote
Tellurian Inc.
TELL
$2.99 (0.34%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.